Genworth Financial Inc Common Stock vs uniQure N.V. Ordinary Shares — how do they compare? Genworth Financial Inc Common Stock trades at $8.82 (market cap $3.36B), while uniQure N.V. Ordinary Shares trades at $20.78 (market cap $1.48B). The key difference: Genworth Financial Inc Common Stock is far larger — about 2.3× uniQure N.V. Ordinary Shares's market cap, and Genworth Financial Inc Common Stock is trading nearer its 52-week high, uniQure N.V. Ordinary Shares nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Genworth Financial Inc Common Stock for 0 Days and uniQure N.V. Ordinary Shares for 0 Days on average.
| GNW | QURE | |
|---|---|---|
Market Cap | $3.36B | $1.48B |
Volume | 3,333,156 | 2,488,780 |
Sector | Financials | Health |
52-Week High | $10.60 | $70.59 |
52-Week Low | $7.94 | $9.03 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $2.87B | $728.62M |
Signals from Pluang's Aura AI — not financial advice
Genworth Financial (GNW) trades at $8.89, down 1.77% today, with neutral technical signals and mixed fundamental performance. The company maintains stable revenue around $7.1-7.2B but faces margin pressure, with net income declining from $223M to $212M year-over-year. Recent Q2 2026 earnings beat expectations at $0.29 EPS, while the company expanded its share repurchase program by $500M in September 2026.
GNW presents value characteristics with low P/B (0.38) and P/S (0.49) ratios, but weak profitability metrics (ROE 2.42%) and analyst caution (70.59% hold rating) suggest limited near-term catalysts. Key risks include legacy insurance liabilities and competitive pressures, while the upcoming Q3 earnings on November 4 could provide directional clarity.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Genworth Financial, Inc. is a holding company that provides products and services related to aging and long-term care planning, and is the parent company of publicly traded mortgage insurer Enact Holdings, Inc.
Read more on GNW →uniQure N.V. is a biotechnology company that develops gene therapies for rare and severe genetic diseases, marketing HEMGENIX for hemophilia B and advancing its AAV-based miQURE platform in programs such as AMT-130 for Huntington's disease.
Read more on QURE →